欧盟与英国的前列腺癌早期检测
该综述综合26项系统评价,覆盖欧盟与英国前列腺癌早期检测的邀请、决策、接受度、筛查试验与算法、危害与获益及未来方向六个主题。基于前列腺特异性抗原的筛查可降低55-69岁随机化男性前列腺癌特异性死亡与转移性疾病,但伴随不必要的穿刺、过度诊断与过度治疗。
要点
- 一般风险男性应在50岁后接受邀请,70岁后或预期寿命不足10年应停止检测。
- 多数卫生当局不鼓励人群筛查,推荐共享决策,但临床实施差异大。
- 风险 adapted 筛查(风险计算器、磁共振成像、血液与尿液生物标志物)可能减少危害。
核心结论
- 通过识别一致与冲突证据,本综述强调了可构建的循证基础以及需要进一步研究和改进的领域,以减轻欧盟与英国的前列腺癌负担。
研究设计与样本
- 2023年6月1日检索四个数据库(Medline ALL via Ovid、Embase、Web of Science、Cochrane Central Register of Controlled Trials)及Google Scholar,仅纳入系统评价(定性、定量和/或荟萃分析),最终纳入26项系统评价。
主要发现
- 一般风险男性应在>50岁时接受邀请,检测应在>70岁或预期寿命<10年时停止。
- 多数卫生当局不鼓励基于人群的筛查,而推荐共享决策方法,但共享决策在临床实践中的实施差异很大。
- 决策辅助工具有助于男性做出更知情且符合价值观的筛查决策,并降低男性尝试筛查的意图,但不影响筛查参与率。
- 在随机化时年龄55-69岁的男性中,若至少筛查两次,基于前列腺特异性抗原的筛查可降低前列腺癌特异性死亡和转移性疾病。
- 这些获益以不必要的穿刺、过度诊断和随后的过度治疗为代价。
关键数值与推荐
- 邀请:一般风险男性>50岁邀请,>70岁或预期寿命<10年停止检测。
- 决策:多数卫生当局不鼓励人群筛查,推荐共享决策。
- 筛查试验:基于前列腺特异性抗原的筛查在随机化时55-69岁男性中若至少筛查两次可降低前列腺癌特异性死亡和转移性疾病。
- 未来方向:风险 adapted 筛查包括(穿刺前)风险计算器、磁共振成像以及血液和尿液生物标志物可能减少危害。
临床怎么用
- 原文未据此给出推荐。
局限性
- 为提供全面概述,本综述聚焦于系统评价,这些系统评价不包括最新的前瞻性研究,因此最新前瞻性研究在讨论部分纳入。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: While prostate cancer (PCa) incidence and mortality rates continue to rise, early detection of PCa remains highly controversial, and the research landscape is rapidly evolving. Existing systematic reviews (SRs) and meta-analyses (MAs) provide valuable insights, but often focus on single aspects of early detection, hindering a comprehensive understanding of the topic. We aim to fill this gap by providing a comprehensive SR of contemporary SRs covering different aspects of early detection of PCa in the European Union (EU) and the UK. METHODS: On June 1, 2023, we searched four databases (Medline ALL via Ovid, Embase, Web of Science, and Cochrane Central Register of Controlled Trials) and Google Scholar. To avoid repetition of previous studies, only SRs (qualitative, quantitative, and/or MAs) were considered eligible. In the data, common themes were identified to present the evidence systematically. KEY FINDINGS AND LIMITATIONS: We identified 1358 citations, resulting in 26 SRs eligible for inclusion. Six themes were identified: (1) invitation: men at general risk should be invited at >50 yr of age, and testing should be discontinued at >70 yr or with <10 yr of life expectancy; (2) decision-making: most health authorities discourage population-based screening and instead recommend a shared decision-making (SDM) approach, but implementation of SDM in clinical practice varies widely; decision aids help men make more informed and value-consistent screening decisions and decrease men's intention to attempt screening, but these do not affect screening uptake; (3) acceptance: facilitators for men considering screening include social prompting by partners and clinician recommendations, while barriers include a lack of knowledge, low-risk perception, and masculinity attributes; (4) screening test and algorithm: prostate-specific antigen-based screening reduces PCa-specific mortality and metastatic disease in men aged 55-69 yr at randomisation if screened at least twice; (5) harms and benefits: these benefits come at the cost of unnecessary biopsies, overdiagnosis, and subsequent overtreatment; and (6) future of screening: risk-adapted screening including (prebiopsy) risk calculators, magnetic resonance imaging, and blood- and urine-based biomarkers could reduce these harms. To enable a comprehensive overview, we focused on SRs. These do not include the most recent prospective studies, which were therefore incorporated in the discussion. CONCLUSIONS AND CLINICAL IMPLICATIONS: By identifying consistent and conflicting evidence, this review highlights the evidence-based foundations that can be built upon, as well as areas requiring further research and improvement to reduce the burden of PCa in the EU and UK. PATIENT SUMMARY: This review of 26 reviews covers various aspects of prostate cancer screening such as invitation, decision-making, screening tests, harms, and benefits. This review provides insights into existing evidence, highlighting the areas of consensus and discrepancies, to guide future research and improve prostate cancer screening strategies in Europe.
引用
- Leenen RCA, Venderbos LDF, Helleman J, et al. Prostate Cancer Early Detection in the European Union and UK. Eur Urol. 2024. PMID: 39183092. doi:10.1016/j.eururo.2024.07.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。